Mr Turnbull was appointed Executive Chairman in November 2006, and has extensive experience in a senior capacity in both public and private companies. First appointed to a fully listed plc board when he was 29 he has enjoyed a 30 year career as a CEO and senior executive. For 15 years he was CEO of Texas Group plc where he was active in numerous acquisitions and flotations. This Manchester based venture capital company was instrumental in the formation and development of Source BioScience in the years prior to its flotation. He is Non-Executive Chairman of CBG Group plc, the Aim quoted insurance broker and financial services company and Non-Executive Chairman of Texas Holdings Ltd.

Dr Ash is the Managing Director of Source BioScience plc, taking up the position in February 2007, having previously been the group’s Chief Financial Officer. A Chartered Accountant with a PhD in Mycology from Sheffield University, Nick has reshaped the group by refocusing activities in the UK, playing a key role in the disposal of the group’s Dubai operations in 2006. Nick has also overseen the acquisition of Geneservice Limited (July 2007) and Autogen Bioclear UK Limited (March 2008) thereby acquiring the technologies and expertise necessary for the group's current and planned range of services. He worked at Eastern Airways and spent nine years with KPMG before joining Source BioScience in 2005.

Dr Leaves is the Operations Director of the Company having held a similar position at Geneservice Limited prior to their acquisition by Source BioScience in July 2007. He joined the Source BioScience Board in June 2008. Before Geneservice, Nick worked for four years as DNA sequencing production manager on high-throughput projects for the Medical Research Council, and worked for five years on Asthma and Eczema gene hunting projects at Oxford University. Prior to this, Nick qualified as a microbiologist and worked in the NHS completing a PhD in 1995 on the molecular methods used to characterise meningitis outbreaks whilst also considering the impact of the HIB meningitis vaccine that has now been introduced UK-wide.

Dr Foden joined the Board in September 2003 following three years with the healthcare Venture Capital firm Merlin Biosciences and 13 years as CEO of Cancer Research Technology. Sue is also a non executive director of Vectura plc, Cellcentric Ltd and of the seed funds Rainbow and Cascade Ltd. She is a member of a number of Advisory Boards including Elara GmbH, CD3 (the joint initiative between EIF and the University of Leuven) and the University of Manchester Premier Fund and is a Trustee of the Institute of Cancer Research. She has an MA and DPhil from the University of Oxford.

Mr Slinger joined the Board as a Non-Executive Director in January 2005. Until June 2004 Mr Slinger had worked for 34 years at the Royal Bank of Scotland plc, as a Director of Corporate Banking. He had specific responsibilities for corporate clients active within the London, New York and Amsterdam exchanges, gaining broad experience in public listings, placements and general corporate activity in acquisitions and disposals. Mr Slinger is an Associate of The Chartered Institute of Bankers and is also a Non-Executive Director of CBG Group plc, which is an insurance company quoted on the Alternative Investment Market of the London Stock Exchange, and a Director of Texas Group plc.